Consolidated Statements of Comprehensive Income (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2012
Income Statement [Abstract]
Net revenues	$ 410,492	$ 424,444	$ 1,240,507		$ 1,287,787
Cost of services sold	220,478	223,889	660,998		679,487
Gross profit	190,014	200,555	579,509		608,300
Selling, general and administrative expenses	(160,820)	(161,207)	(482,634)		(498,842)
Goodwill, intangibles and other long-lived asset impairment	0	(19,132)	(224,320)	[1]	(19,132)
Gain on sale of businesses	0	0	0		5,447
Interest income	639	653	2,066		2,011
Interest expense and other	(22,981)	(23,547)	(68,849)		(69,062)
Income (loss) before income taxes and equity in net earnings of CareCentrix	6,852	(2,678)	(194,228)		28,722
Income tax (expense) benefit	(3,044)	1,297	(2,457)		(10,878)
Equity in net earnings of CareCentrix	0	1,006	0		1,006
Net income (loss)	3,808	(375)	(196,685)		18,850
Less: Net income attributable to noncontrolling interests	(88)	(148)	(425)		(624)
Net income (loss) attributable to Gentiva shareholders	3,720	(523)	(197,110)		18,226
Comprehensive income (loss)	$ 3,808	$ (375)	$ (196,685)		$ 18,850
Net income (loss) attributable to Gentiva shareholders:
Basic	$ 0.12	$ (0.02)	$ (6.38)		$ 0.60
Diluted	$ 0.12	$ (0.02)	$ (6.38)		$ 0.60
Weighted average shares outstanding:
Basic	31,037	30,423	30,921		30,496
Diluted	31,532	30,423	30,921		30,612

[1] (2)At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $220.8 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. See Note 9.In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.Hospice and corporate assets were reduced by $220.8 million and $3.5 million, respectively, as a result of the impairment.For both the third quarter and first nine months of 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of September 30, 2012 as a result of the impairment.